Although our study provides the first thorough characterisation of APLN/APLNR expression in renal cell carcinoma (especially in ccRCC as the dominant subtype) and its association with clinicopathological variables and outcome, functional studies, especially those related to the associated immune processes, were not within the scope of our project and warrant further investigations. Here, APLNR is linked to renal cell carcinoma.